Voloridge Investment Management
VRTX icon

Voloridge Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Voloridge Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-105,502
Closed -$41.3M – 1373
2025
Q3 		$41.3M Buy
+105,502
New +$44.1M 0.14% 180
2025
Q1 		– Sell
-69,712
Closed -$28.1M – 1382
2024
Q4 		$28.1M Sell
69,712
-67,376
-49% -$31.2M 0.1% 265
2024
Q3 		$63.8M Buy
137,088
+87,312
+175% +$41.9M 0.23% 110
2024
Q2 		$23.3M Sell
49,776
-51,401
-51% -$22.3M 0.09% 315
2024
Q1 		$42.3M Buy
101,177
+19,827
+24% +$8.38M 0.15% 191
2023
Q4 		$33.1M Buy
81,350
+48,597
+148% +$18M 0.13% 205
2023
Q3 		$11.4M Buy
32,753
+18,753
+134% +$6.56M 0.06% 428
2023
Q2 		$4.93M Buy
+14,000
New +$4.72M 0.02% 677
2023
Q1 		– Sell
-60,891
Closed -$17.6M – 1637
2022
Q4 		$17.6M Buy
+60,891
New +$18.6M 0.1% 292
2022
Q3 		– Sell
-21,735
Closed -$6.13M – 1634
2022
Q2 		$6.13M Buy
+21,735
New +$5.82M 0.03% 603
2022
Q1 		– Sell
-139,353
Closed -$30.6M – 1730
2021
Q4 		$30.6M Sell
139,353
-397,543
-74% -$77.3M 0.17% 156
2021
Q3 		$97.4M Buy
536,896
+284,222
+112% +$55.5M 0.63% 11
2021
Q2 		$50.9M Buy
252,674
+43,799
+21% +$9.16M 0.35% 40
2021
Q1 		$44.9M Sell
208,875
-51,910
-20% -$11.4M 0.33% 61
2020
Q4 		$61.6M Buy
260,785
+195,175
+297% +$44.8M 0.52% 31
2020
Q3 		$17.9M Buy
+65,610
New +$18.1M 0.15% 168
2020
Q1 		– Sell
-97,763
Closed -$21.4M – 1430
2019
Q4 		$21.4M Buy
+97,763
New +$19.8M 0.42% 39
2018
Q1 		– Sell
-287,899
Closed -$43.1M – 671
2017
Q4 		$43.1M Sell
287,899
-4,858
-2% -$719K 0.94% 17
2017
Q3 		$44.5M Buy
+292,757
New +$44.1M 0.99% 19
2016
Q2 		– Sell
-79,032
Closed -$6.28M – 409
2016
Q1 		$6.28M Buy
+79,032
New +$7.15M 0.15% 131

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Voloridge Investment Management's VRTX Position: Q4 2025 in Review

Voloridge Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 105,502 shares — an estimated $41.3M sold.

Voloridge Investment Management first reported a position in VRTX in Q1 2016 and held it in 20 quarters. The position peaked at $97.4M in Q3 2021. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Voloridge Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 105,502 Vertex Pharmaceuticals shares in Q4 2025, an estimated $41.3M.
  • Voloridge Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 20 quarters.
  • Voloridge Investment Management's Vertex Pharmaceuticals position peaked at $97.4M in Q3 2021.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Voloridge Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.